Merck & Co Inc (MRK)
98.05
-1.47
(-1.48%)
USD |
NYSE |
Dec 20, 16:00
98.88
+0.83
(+0.85%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 248.03B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -4.40% |
| Valuation | |
| PE Ratio | 20.56 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 3.946 |
| Price to Book Value | 5.574 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.81 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8568 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 27.26% |
Profile
| Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States. |
| URL | https://www.merck.com |
| Investor Relations URL | https://www.merck.com/investor-relations |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Feb. 04, 2025 |
| Last Earnings Release | Oct. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 16, 2024 |
Ratings
Profile
| Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States. |
| URL | https://www.merck.com |
| Investor Relations URL | https://www.merck.com/investor-relations |
| HQ State/Province | New Jersey |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Feb. 04, 2025 |
| Last Earnings Release | Oct. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Dec. 16, 2024 |